证券代码：300841 证券简称：康华生物 公告编号：2025-050 成都康华生物制品股份有限公司 2025年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及《深圳 证券交易所创业板上市公司自律监管指南第 2 号——公告格式》的相关规定，成 都康华生物制品股份有限公司（以下简称"公司"）就 2025 年半年度募集资金 存放与使用情况作如下专项报告： 一、募集资金基本情况 (一)实际募集资金金额和资金到账时间 公司经中国证券监督管理委员会证监许可[2020]521 号《关于核准成都康华 生物制品股份有限公司首次公开发行股票的批复》核准，首次公开发行人民币普 通股（A 股）1,500.00 万股，每股发行价为人民币 70.37 元，发行新股 1,500.00 万股，共募集资金总额为人民币 105,555.00 万元，扣除各项发行费用人民币 7,457.70 万元后，募集资金净额为人民币 9 ...

2 0 24年 度 环 境 、 社 会 （E 2 0 24 E N VIR O N M E N T A L, S O CIAL A ND C O R P O R A TE G O V E R N A N CE ( E S G) R E P O R T | 股东权益保护 | 17 | | --- | --- | | 利益相关方 | 17 | | 企业荣誉 | 19 | | 4.可持续发展管理 | 23 | | 可持续发展管理策略 | 23 | | 可持续发展管理理念 | 23 | | 实质性议题分析 | 23 | | ESG治理架构 | 25 | | 董事会声明 | 26 | 成 都 康 华 生 物 制 品 股 份 有 限 公 司 CHENGDU KANGHUA BIOLOGICAL PRODUCTS CO., LTD 地址：四川省成都经济技术开发区北京路182号 邮编：610100 电话：028-84846555（总机）或028-84882755 传真： （86）028-84846577 公司官网： www.kangh.com 邮箱：contact@kangh.com 2 0 2 4 及 公 司 治 理 S ...

本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届监事会第七次会 议通知已于2025年8月12日以电邮和专人通知方式向全体监事发出。会议于2025 年8月22日以现场与线上会议相结合方式召开。会议由监事会主席吴淑青女士召 集并主持，会议应出席监事3名，实际出席监事3名。本次会议的召集、召开程序 符合《中华人民共和国公司法》等法律、法规、规范性文件和《成都康华生物制 品股份有限公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 证券代码：300841 证券简称：康华生物 公告编号：2025-046 成都康华生物制品股份有限公司 第三届监事会第七次会议决议公告 经与会监事认真讨论，审议并通过如下议案： （一） 审议通过《关于2025年半年度报告及其摘要的议案》 公司编制和审核2025年半年度报告及其摘要的程序符合法律、行政法规、中 国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（www. ...

证券代码：300841 证券简称：康华生物 公告编号：2025-045 成都康华生物制品股份有限公司 第三届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 成都康华生物制品股份有限公司（以下简称"公司"）第三届董事会第七次 会议通知于2025年8月12日以电邮和专人通知的方式向全体董事和监事发出，会 议于2025年8月22日以现场与线上会议相结合方式召开。本次会议由董事长王振 滔先生召集并主持，会议应出席董事8人，实际出席董事8人，公司监事、高级管 理人员列席了本次会议。本次会议的召集和召开程序符合《中华人民共和国公司 法》、《成都康华生物制品股份有限公司章程》等有关规定，会议合法、有效。 二、 董事会会议审议情况 （一）审议通过《关于 2025 年半年度报告及其摘要的议案》 公司 2025 年半年度报告编制和审核的程序符合相关法律法规，报告内容真 实、准确、完整地反映了公司 2025 年半年度经营的实际情况，不存在虚假记载、 误导性陈述或重大遗漏。 本议案已经第三届董事会审计委员会第四次会议审议通过。 具体 ...

Financial Performance - Revenue for the reporting period was ¥483,918,966.75, a decrease of 34.70% compared to ¥741,084,779.28 in the same period last year[26]. - Net profit attributable to shareholders was ¥114,520,580.49, down 62.64% from ¥306,554,841.90 year-on-year[26]. - Basic earnings per share decreased by 61.76% to ¥0.8813 from ¥2.3049 in the previous year[26]. - The net cash flow from operating activities was ¥65,322,487.72, a decline of 62.84% compared to ¥175,791,019.36 in the same period last year[26]. - Total assets at the end of the reporting period were ¥3,836,901,026.55, down 4.73% from ¥4,027,582,273.97 at the end of the previous year[26]. - The company reported a decrease in vaccine sales revenue of 23.79% compared to the same period last year, after excluding the previous year's revenue from overseas licensing of ¥106,240,500.00[26]. - The weighted average return on net assets was 3.29%, down 5.27% from 8.56% in the previous year[26]. - The company’s revenue for the reporting period was CNY 484.92 million, a year-on-year decrease of 34.70%, with Q2 revenue at CNY 345.98 million, up 150.81% from Q1[41]. - Net profit attributable to shareholders was CNY 114.52 million, down 62.64% year-on-year, with Q2 net profit at CNY 93.81 million, an increase of 353.01% from Q1[41]. Research and Development - The company reported a significant focus on product innovation and process improvement to enhance vaccine safety and production efficiency[6]. - The management emphasizes the importance of reducing R&D risks through market-oriented product development and collaboration[6]. - The report highlights the long and challenging R&D cycle for vaccine products, indicating inherent uncertainties in achieving successful commercialization[6]. - The company has established multiple vaccine research and development platforms and has participated in national and provincial technology projects, enhancing its innovation capabilities[38]. - The company has optimized its R&D organizational structure to strengthen its independent research capabilities and accelerate the development of new products[42]. - The company is advancing the clinical trials for the six-valent norovirus vaccine and plans to submit for clinical trials for the human rabies vaccine using fixed bioreactor culture technology[43]. - The company has a research and development pipeline that includes multiple innovative vaccine platforms, such as mRNA, recombinant protein VLP, polysaccharide-protein conjugate, live attenuated, inactivated vaccines, and new adjuvant platforms[49]. Market Strategy - The company continues to focus on expanding its market presence and enhancing competitive advantages in the vaccine sector[8]. - The company is actively pursuing diverse international expansion strategies, including finished product exports and local production collaborations[36]. - The company aims to enhance its market expansion strategies and product development in the upcoming quarters to recover from the current downturn[148]. - The company is focusing on enhancing brand influence and market penetration to solidify its leading position in the human diploid rabies vaccine sector[45]. Risk Management - The company has a structured approach to risk management, particularly regarding product sales and market competition[7]. - The company faces risks due to a relatively narrow product structure, primarily relying on the rabies vaccine, which may be impacted by increased competition from other manufacturers[78]. - The company has established a quality control system in compliance with relevant laws to manage product quality and adverse reaction events[80]. - The company has implemented a multi-level compliance management mechanism to enhance its risk management capabilities and ensure sustainable, high-quality development[51]. Corporate Governance - The financial report is guaranteed to be accurate and complete by the company's leadership, ensuring accountability[5]. - The company plans to maintain its current dividend policy, opting not to distribute cash dividends or issue bonus shares[9]. - The company held one shareholders' meeting during the reporting period, ensuring compliance with relevant laws and regulations, and actively protecting the rights of minority shareholders[90]. - The company has approximately 600 employees and continuously improves systems to protect employee rights, including mandatory social insurance and various benefits[91]. Financial Management - The company has committed to specific projects funded by the raised capital, with ongoing adjustments to the investment amounts as necessary[67]. - The company has adjusted the completion date of the "Kanghua Biological Vaccine Production Expansion Project" from October 20, 2023, to December 31, 2024[69]. - The company is focused on ensuring the effective use of raised funds and has not encountered any major changes in project feasibility[69]. - The company has set aside 2.25 million for general risk reserves, indicating a proactive approach to financial management[158]. - The company plans to increase its capital reserves by transferring surplus reserves to capital, enhancing its financial strength[163]. Compliance and Legal Matters - The semi-annual financial report was not audited[101]. - The company did not experience any major litigation or arbitration matters during the reporting period[103]. - There were no penalties or rectification situations reported during the period[104]. - The company did not engage in any significant related party transactions during the reporting period[105]. Shareholder Information - The total number of restricted shares decreased from 12,454,048 (9.37%) to 11,017,624 (8.29%), a reduction of 1,436,424 shares[124]. - The total number of unrestricted shares increased from 120,492,851 (90.63%) to 121,929,275 (91.71%), an increase of 1,436,424 shares[124]. - The total number of shares outstanding remained unchanged at 132,946,899 (100.00%) after the adjustments[124]. - The largest shareholder, Aokang Group Co., Ltd., holds 12.26% of shares, totaling 16,305,468 shares[130]. - Wang Zhentao, a significant shareholder, owns 10.53% of shares, amounting to 14,004,680 shares[130].

Core Viewpoint - The stock market is experiencing a bullish trend, with the Shanghai Composite Index surpassing 3700 points, while a notable increase in shareholding reduction announcements from major shareholders of listed biopharmaceutical companies is observed [1] Company Summaries - Over 30 biopharmaceutical companies have announced shareholder reduction plans since August 1, with several companies reducing their holdings by 3% or more [1][2] - Key companies with significant shareholder reductions include: - Linuo Pharmaceutical: 840.73 thousand shares (3.61%) - Kangtai Medical: 1,441.6 thousand shares (3.59%) - Shengyin Meisi: 509.45 thousand shares (3.04%) - Chenxin Pharmaceutical: 1,358.26 thousand shares (3.95%) - Ailis: 1,350 thousand shares (3%) - Kanghua Biological: 389.84 thousand shares (3%) [2] - Kanghua Biological's major shareholder, Sichuan Development Securities Investment Fund Management Co., plans to reduce its holdings by up to 3,898,405 shares (3% of total shares) within three months [3] - The company has faced a decline in performance, with a 43.83% drop in the issuance of its main product, the freeze-dried human rabies vaccine, leading to a 9.23% decrease in revenue to 1.432 billion yuan and a 21.71% drop in net profit to 399 million yuan in 2024 [5] - The competitive landscape for rabies vaccines is intensifying, with new entrants like Shenzhen Kangtai Biological Products Co. launching similar products, which may further challenge Kanghua Biological's market position [5][6]

Group 1 - The animal vaccine sector experienced a decline of 0.72% as of the market close on August 22, ranking among the top declines in concept sectors [1] - Within the animal vaccine sector, companies such as Shenlian Biological, Weilan Biological, and Xianfeng Holdings saw significant declines, while Kexing Pharmaceutical, Haizheng Pharmaceutical, and Guoyao Modern recorded increases of 2.06%, 0.44%, and 0.09% respectively [1] - The overall market saw a net outflow of 0.68 billion yuan from the animal vaccine sector, with 11 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net outflow in the animal vaccine sector was from Kanghua Biological, with a net outflow of 30.50 million yuan, followed by Shenlian Biological, Dabeinong, and Jinhai Biological with outflows of 27.38 million yuan, 24.27 million yuan, and 23.53 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Luoniushan, with net inflows of 27.34 million yuan, 16.70 million yuan, and 10.38 million yuan respectively [3] - The trading activity in the animal vaccine sector showed that Kanghua Biological had a turnover rate of 3.52% and a decline of 1.70%, while Kexing Pharmaceutical had a turnover rate of 3.12% and an increase of 2.06% [3]

Group 1 - The latest stock price of Kanghua Biotech is 86.24 yuan, an increase of 2.54 yuan or 3.03% from the previous trading day. The intraday high reached 87.52 yuan and the low was 83.70 yuan, with a trading volume of 527 million yuan and a turnover rate of 5.13% [1] - Kanghua Biotech operates in the biopharmaceutical sector, focusing on the research, production, and sales of human vaccines. Its main products include rabies vaccines and Japanese encephalitis vaccines, and the company is actively expanding into the pet vaccine market [1] - The Shanghai Biopharmaceutical M&A Fund strategically took control of Kanghua Biotech in July, with plans to accelerate the diversification of the vaccine product line and build a vaccine ecosystem. This collaboration is seen as a significant move by Shanghai state-owned assets in the biopharmaceutical field [1] Group 2 - On August 21, Kanghua Biotech experienced a net inflow of 37.11 million yuan in main funds, accounting for 0.36% of its circulating market value. However, over the past five days, there was a net outflow of 114 million yuan, representing 1.11% of its circulating market value [1]

Group 1 - The stock price of Kanghua Biotech is reported at 85.99 yuan as of August 19, 2025, showing a decline of 1.35% from the previous trading day with a trading volume of 650 million yuan [1] - The company operates in the biopharmaceutical industry, focusing on the research, production, and sales of vaccines and biological products, primarily in human and pet vaccine sectors, with a market presence in both domestic and some overseas regions [1] - On the morning of August 19, the stock experienced a rapid decline around 9:47 AM, dropping over 2% within 5 minutes, reaching a low of 88.22 yuan with a transaction volume of 178 million yuan [1] Group 2 - On August 19, the net outflow of main funds was 56.87 million yuan, accounting for 0.56% of the circulating market value, with a cumulative net outflow of 9.80 million yuan over the past five trading days [1]

Group 1 - The core viewpoint of the news is that Kanghua Biological (300841) has experienced a significant decline in revenue and net profit in its latest quarterly report, indicating potential challenges for the company moving forward [1] - As of August 15, 2025, Kanghua Biological's stock closed at 92.06 yuan, up 3.67%, with a turnover rate of 5.31% and a trading volume of 63,100 hands, amounting to a transaction value of 574 million yuan [1] - The company reported total operating revenue of 138 million yuan for the first quarter of 2025, a year-on-year decrease of 55.70%, and a net profit attributable to shareholders of 20.71 million yuan, down 86.15% year-on-year [1] Group 2 - Kanghua Biological has a current liquidity ratio of 5.797 and a quick ratio of 5.334, indicating strong short-term financial health, while its debt-to-asset ratio stands at 10.70% [1] - The company has made investments in five enterprises and has participated in 646 bidding projects, showcasing its active engagement in the market [2] - Kanghua Biological holds 67 trademark registrations and 253 patents, along with 402 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]